I'm not sure how this one compares to Leronlimab f

I'm not sure how this one compares to Leronlimab for HIV, but a few non- medical thoughts: (1) Viiv Healthcare had a chance of being approved must sooner than today, but in December 2019 Viiv received a complete response letter from FDA and cost them an extra year; (2) Viiv is privately owned and does nothing but work on HIV; (3) Viiv is majority owned by GlaxoSmithKline, so once our BLA gets re-filed with FDA I would guess that GSK will take lots of notice of Leronlimab; and MOST IMPORTANTLY: (4) when our wonderful CD12 data is released, I won't be thinking at all about Viiv!